DYRK1A inhibitors for disease therapy: Current status and perspectives

T Liu, Y Wang, J Wang, C Ren, H Chen… - European journal of …, 2022 - Elsevier
Dual-specificity tyrosine phosphorylation-regulated kinase 1 A (DYRK1A) is a conserved
protein kinase that plays essential roles in various biological processes. It is located in the …

GSK-3β, FYN, and DYRK1A: master regulators in neurodegenerative pathways

S Demuro, RMC Di Martino, JA Ortega… - International journal of …, 2021 - mdpi.com
Protein kinases (PKs) have been recognized as central nervous system (CNS)-disease-
relevant targets due to their master regulatory role in different signal transduction cascades …

A small molecule produced by Lactobacillus species blocks Candida albicans filamentation by inhibiting a DYRK1-family kinase

J MacAlpine, M Daniel-Ivad, Z Liu, J Yano… - Nature …, 2021 - nature.com
The fungus Candida albicans is an opportunistic pathogen that can exploit imbalances in
microbiome composition to invade its human host, causing pathologies ranging from vaginal …

Silmitasertib (CX-4945), a clinically used CK2-kinase inhibitor with additional effects on GSK3β and DYRK1A kinases: A structural perspective

P Grygier, K Pustelny, J Nowak, P Golik… - Journal of medicinal …, 2023 - ACS Publications
A clinical casein kinase 2 inhibitor, CX-4945 (silmitasertib), shows significant affinity toward
the DYRK1A and GSK3β kinases, involved in down syndrome phenotypes, Alzheimer's …

DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome

A Duchon, Y Herault - Frontiers in behavioral neuroscience, 2016 - frontiersin.org
Down syndrome (DS) is one of the leading causes of intellectual disability, and patients with
DS face various health issues, including learning and memory deficits, congenital heart …

Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors as potential therapeutics

DB Jarhad, KK Mashelkar, HR Kim… - Journal of medicinal …, 2018 - ACS Publications
Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is a member of an
evolutionarily conserved family of protein kinases that belongs to the CMGC group of …

Therapeutic potential of quinazoline derivatives for Alzheimer's disease: A comprehensive review

Z Haghighijoo, L Zamani, F Moosavi… - European journal of …, 2022 - Elsevier
Quinazolines are considered as a promising class of bioactive heterocyclic compounds with
broad properties. Particularly, the quinazoline scaffold has an impressive role in the design …

Psychedelic‐inspired approaches for treating neurodegenerative disorders

HN Saeger, DE Olson - Journal of neurochemistry, 2022 - Wiley Online Library
Psychedelics are increasingly being recognized for their potential to treat a wide range of
brain disorders including depression, post‐traumatic stress disorder (PTSD), and substance …

DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications

R Abbassi, TG Johns, M Kassiou, L Munoz - Pharmacology & therapeutics, 2015 - Elsevier
Protein kinases are one of the most studied drug targets in current pharmacological
research, as evidenced by the vast number of kinase-targeting agents enrolled in active …

Selective DYRK1A inhibitor for the treatment of Type 1 Diabetes: Discovery of 6-azaindole derivative GNF2133

YA Liu, Q Jin, Y Zou, Q Ding, S Yan… - Journal of medicinal …, 2020 - ACS Publications
Autoimmune deficiency and destruction in either β-cell mass or function can cause
insufficient insulin levels and, as a result, hyperglycemia and diabetes. Thus, promoting β …